Johnson & Johnson
强生公司
Johnson & Johnson appears in elsewhere's corpus primarily through its pharmaceutical operations and as a career waypoint for Chinese biotech investors. The company partnered with AI drug-discovery firm XtalPi in 2022, with Janssen Research & Development (a J&J subsidiary) tapping XtalPi for computational design and screening of novel small-molecule compounds targeting specific biological targets . Kan Chen, now a partner at Qiming Venture Partners, spent his early career as a senior scientist at J&J in the United States working on oncology drug R&D before moving to venture capital . J&J also shows up as a participant in industry events alongside Chinese VCs and tech firms . elsewhere's corpus does not contain a broader corporate profile or recent strategic overview of the company.
AI-generated — may contain errors, please verify.
Coverage
November, a World of Infinite Possibilities | 5Y News Monthly
The big news from last month.
五源资本·Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
暗涌Waves·"AI + Vertical Industry Applications" Salon Recap: What's Changing in Marketing, Law, and Healthcare?
Since ChatGPT's official launch, the generative AI-driven entrepreneurship wave has continued to spread globally — and after 300 days, the赛道 remains as hot as ever. The long-term value proposition that **generative AI will transform productivity** has become an industry consensus. Yet the road ahead is long. The harder questions behind this revolution are how to **translate technology into real-world deployment, accelerate the development of innovative applications in vertical scenarios, and achieve commercialization**.
线性资本·Beyond What Meets the Eye | 5Y News Monthly
The big news from last month.
五源资本·5Y News | moody宣布完成超10亿人民币C轮融资
如何两年跃升行业冠军？
五源资本·
